AOD-9604 half-life & pharmacokinetics

Reported half-life

Approximately 30 minutes following subcutaneous injection in human pharmacokinetic studies; rapid renal clearance consistent with its small size (1815 Da).

The half-life and pharmacokinetic profile of AOD-9604 reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection
• Intra-articular injection (cartilage research)
• Oral (historical obesity trials — low bioavailability)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Human growth hormone C-terminal fragment analogue; lipolytic peptide; chondroprotective research compound

Mechanism context

Half-life interpretation depends on the underlying mechanism. AOD-9604 acts as follows:

AOD-9604 is a modified 16-amino-acid peptide corresponding to the C-terminal region of human growth hormone (hGH residues 177–191 with an additional N-terminal tyrosine). Its development was premised on the observation that the lipolytic activity of hGH could be separated from its growth-promoting and insulin-like properties, which are principally mediated through GH receptor binding in the N-terminal and mid-molecule regions.

See the full AOD-9604 research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.